You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
北海康成通過港交所上市聆訊
格隆匯 11-18 11:31
格隆匯11月18日丨據港交所文件顯示,專注於罕見病用藥的北海康成通過港交所上市聆訊,摩根士丹利和傑富瑞爲其聯席保薦人。 北海康成成立於2012年,是立足中國、專注於罕見病的生物醫藥公司,致力於研究、開發及商業化生物科技療法。截至最後實際可行日期,公司已打造一個由13個擁有巨大市場潛力的藥物資產組成的全面的管線,包括三個已上市產品、四個處於臨牀階段的候選藥物、一個處於IND準備階段、兩個處於臨牀前階段,另外三個基因治療項目處於先導識別階段。公司的產品及候選產品針對部分最常見的罕見病以及罕見的腫瘤適應症,包括但不限於膠質母細胞瘤(GBM)及黏多糖貯積症II型(MPS II或亨特氏綜合症)。商業化進展方面,公司重磅產品Hunterase(CAN101)去年9月在中國獲批上市,用於治療MPSⅡ(亨特綜合徵)。這是北海康成在中國成功商業化的第一款罕見病藥物,也是國內首個且唯一的全球新一代治療MPSⅡ的酶替代療法,擁有FDA孤兒藥資格認證,且在此前獲得國家藥監局的優先審評資格,填補了我國在MPSⅡ適應症臨牀治療領域的空白。 值得注意的是,中國CXO龍頭藥明康德持有北海康成10.97%股份,是北海康成佔股最大的外部投資者。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account